Overview
Clinical Benefits
- Superior weight loss vs Semaglutide alone
- Dual mechanism appetite suppression
- Slows gastric emptying via 2 pathways
- Once-weekly convenience
Administration
Subcutaneous injection — abdomen, thigh, or upper arm
Drug class: multi peptide blend
Clinical Dosing
Typical dosage
Titrate to 2.4mg/2.4mg weekly
Starting dose
0.25mg Sema + 0.16mg Cagri
Cadence
Once weekly
Full titration schedule
| Phase | Dose |
|---|---|
| Weeks 1-4 | 0.25mg Sema + 0.16mg Cagri once weekly |
| Weeks 5-8 | 0.5mg Sema + 0.3mg Cagri once weekly |
| Weeks 9-12 | 1.0mg Sema + 0.6mg Cagri once weekly |
| Weeks 13-16 | 1.7mg Sema + 1.2mg Cagri once weekly |
| Weeks 17+ | 2.4mg Sema + 2.4mg Cagri once weekly (maintenance) |
Safety Profile
Side effects
- • Nausea (more pronounced than Sema alone)
- • Vomiting
- • Diarrhea or constipation
- • Injection site reactions
Contraindications
- • Pregnancy
- • Pancreatitis history
- • Severe GI disease
- • MTC (medullary thyroid cancer) history
- • MEN2 syndrome
Do not combine with
Frequently asked questions
CagriSema Blend is most commonly researched for: Superior weight loss vs Semaglutide alone, Dual mechanism appetite suppression, Slows gastric emptying via 2 pathways, Once-weekly convenience.
Ready to build a protocol with CagriSema Blend?
LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.
You’ll be asked to sign in first. Free tier includes the chat preview.
Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.